Literature DB >> 34253712

TAZ inhibits osteoclastogenesis by attenuating TAK1/NF-κB signaling.

Wanlei Yang1, Xuanyuan Lu1, Tan Zhang1, Weiqi Han1, Jianlei Li1, Wei He1, Yewei Jia1, Kangxian Zhao1, An Qin2, Yu Qian3.   

Abstract

Osteoporosis is an osteolytic disorder commonly associated with excessive osteoclast formation. Transcriptional coactivator with PDZ-binding motif (TAZ) is a key downstream effector of the Hippo signaling pathway; it was suggested to be involved in the regulation of bone homeostasis. However, the exact role of TAZ in osteoclasts has not yet been established. In this study, we demonstrated that global knockout and osteoclast-specific knockout of TAZ led to a low-bone mass phenotype due to elevated osteoclast formation, which was further evidenced by in vitro osteoclast formation assays. Moreover, the overexpression of TAZ inhibited RANKL-induced osteoclast formation, whereas silencing of TAZ reduced it. Mechanistically, TAZ bound to TGF-activated kinase 1 (TAK1) and reciprocally inhibited NF-κB signaling, suppressing osteoclast differentiation. Collectively, our findings highlight an essential role of TAZ in the regulation of osteoclastogenesis in osteoporosis and its underlying mechanism.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34253712     DOI: 10.1038/s41413-021-00151-3

Source DB:  PubMed          Journal:  Bone Res        ISSN: 2095-4700            Impact factor:   13.567


  41 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 2.  Osteoporosis: now and the future.

Authors:  Tilman D Rachner; Sundeep Khosla; Lorenz C Hofbauer
Journal:  Lancet       Date:  2011-03-28       Impact factor: 79.321

3.  Role of TAZ as mediator of Wnt signaling.

Authors:  Luca Azzolin; Francesca Zanconato; Silvia Bresolin; Mattia Forcato; Giuseppe Basso; Silvio Bicciato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Cell       Date:  2012-12-13       Impact factor: 41.582

4.  The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version.

Authors:  Bin Zhao; Li Li; Qunying Lei; Kun-Liang Guan
Journal:  Genes Dev       Date:  2010-05       Impact factor: 11.361

5.  TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins.

Authors:  F Kanai; P A Marignani; D Sarbassova; R Yagi; R A Hall; M Donowitz; A Hisaminato; T Fujiwara; Y Ito; L C Cantley; M B Yaffe
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

6.  The Hippo pathway regulates Wnt/beta-catenin signaling.

Authors:  Xaralabos Varelas; Bryan W Miller; Richelle Sopko; Siyuan Song; Alex Gregorieff; Frederic A Fellouse; Rui Sakuma; Tony Pawson; Walter Hunziker; Helen McNeill; Jeffrey L Wrana; Liliana Attisano
Journal:  Dev Cell       Date:  2010-04-20       Impact factor: 12.270

Review 7.  NF-κB signaling and bone resorption.

Authors:  Y Abu-Amer
Journal:  Osteoporos Int       Date:  2013-03-07       Impact factor: 4.507

Review 8.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer.

Authors:  Fa-Xing Yu; Bin Zhao; Kun-Liang Guan
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

9.  NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway.

Authors:  Sandra Habbig; Malte P Bartram; Roman U Müller; Ricarda Schwarz; Nikolaos Andriopoulos; Shuhua Chen; Josef G Sägmüller; Martin Hoehne; Volker Burst; Max C Liebau; H Christian Reinhardt; Thomas Benzing; Bernhard Schermer
Journal:  J Cell Biol       Date:  2011-05-09       Impact factor: 10.539

10.  Autoamplification of NFATc1 expression determines its essential role in bone homeostasis.

Authors:  Masataka Asagiri; Kojiro Sato; Takako Usami; Sae Ochi; Hiroshi Nishina; Hiroki Yoshida; Ikuo Morita; Erwin F Wagner; Tak W Mak; Edgar Serfling; Hiroshi Takayanagi
Journal:  J Exp Med       Date:  2005-11-07       Impact factor: 14.307

View more
  5 in total

Review 1.  The Role of TAK1 in RANKL-Induced Osteoclastogenesis.

Authors:  Wu Jianwei; Tian Ye; Wang Hongwei; Li Dachuan; Zou Fei; Jiang Jianyuan; Wang Hongli
Journal:  Calcif Tissue Int       Date:  2022-03-14       Impact factor: 4.000

2.  Bortezomib Rescues Ovariectomy-Induced Bone Loss via SMURF-Mediated Ubiquitination Pathway.

Authors:  Yuepeng Fang; Yang Liu; Zhijian Zhao; Yingjie Lu; Xu Shen; Tianfeng Zhu; Mingzhuang Hou; Fan He; Huilin Yang; Yijian Zhang; Qin Shi; Xuesong Zhu
Journal:  Oxid Med Cell Longev       Date:  2021-12-31       Impact factor: 6.543

3.  Phosphorylation of BCL2 at the Ser70 site mediates RANKL-induced osteoclast precursor autophagy and osteoclastogenesis.

Authors:  Dianshan Ke; Yunlong Yu; Chenglong Li; Junyong Han; Jie Xu
Journal:  Mol Med       Date:  2022-02-19       Impact factor: 6.354

4.  Azilsartan Suppresses Osteoclastogenesis and Ameliorates Ovariectomy-Induced Osteoporosis by Inhibiting Reactive Oxygen Species Production and Activating Nrf2 Signaling.

Authors:  Bin Pan; Lin Zheng; Jiawei Fang; Ye Lin; Hehuan Lai; Jiawei Gao; Wenzheng Pan; Yejin Zhang; Kainan Ni; Chao Lou; Dengwei He
Journal:  Front Pharmacol       Date:  2021-11-26       Impact factor: 5.810

5.  TiO2 Nanotubes Promote Osteogenic Differentiation Through Regulation of Yap and Piezo1.

Authors:  Keyu Kong; Yongyun Chang; Yi Hu; Hua Qiao; Chen Zhao; Kewei Rong; Pu Zhang; Jingwei Zhang; Zanjing Zhai; Huiwu Li
Journal:  Front Bioeng Biotechnol       Date:  2022-04-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.